Literature DB >> 20833935

Management of psychosis associated with a prolactinoma: case report and review of the literature.

Shirin Ali1, Karen Klahr Miller, Oliver Freudenreich.   

Abstract

BACKGROUND: Prolactinomas are the most common pituitary tumors; they are treated with dopamine agonists, which may cause psychotic symptoms as a side effect. Psychosis is treated with dopamine-receptor blockers that may result in elevated serum prolactin and symptomatic hyperprolactinemia.
OBJECTIVE: The authors will review a case of a patient with a prolactinoma as well as schizophrenia and illustrate the management of psychosis in this case.
METHOD: The review describes the management of prolactinoma, symptoms of hyperprolactinemia, and long-term effects of hyperprolactinemia.
RESULTS: In the case presentation reviewed, the patient was finally discharged on risperidone long-acting injection and testosterone supplementation, with no growth of the adenoma after 3 years. DISCUSSION: This review provides recommendations and treatment strategy for management of prolactinoma in a patient with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20833935      PMCID: PMC3667992          DOI: 10.1176/appi.psy.51.5.370

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  37 in total

1.  Galactorrhea with aripiprazole.

Authors:  Anselmo Ruffatti; Lina Minervini; Maria Romano; Nicoletta Sonino
Journal:  Psychother Psychosom       Date:  2005       Impact factor: 17.659

2.  Valvular heart disease and the use of dopamine agonists for Parkinson's disease.

Authors:  Renzo Zanettini; Angelo Antonini; Gemma Gatto; Rosa Gentile; Silvana Tesei; Gianni Pezzoli
Journal:  N Engl J Med       Date:  2007-01-04       Impact factor: 91.245

3.  Bromocriptine treatment of relapses seen during selective serotonin re-uptake inhibitor treatment of depression.

Authors:  P J McGrath; F M Quitkin; D F Klein
Journal:  J Clin Psychopharmacol       Date:  1995-08       Impact factor: 3.153

4.  Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder.

Authors:  K Melkersson; A L Hulting
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2000       Impact factor: 5.270

5.  Cabergoline and the risk of valvular lesions in endocrine disease.

Authors:  Patrizio Lancellotti; Elena Livadariu; Muriel Markov; Adrian F Daly; Maria-Cristina Burlacu; Daniela Betea; Luc Pierard; Albert Beckers
Journal:  Eur J Endocrinol       Date:  2008-05-02       Impact factor: 6.664

6.  The effect of thioridazine on prolactinoma growth in a schizophrenic man: case report.

Authors:  J C Weingarten; T L Thompson
Journal:  Gen Hosp Psychiatry       Date:  1985-10       Impact factor: 3.238

7.  Cabergoline-induced psychotic exacerbation in schizophrenic patients.

Authors:  Shen-Chieh Chang; Chun-Hsin Chen; Mong-Liang Lu
Journal:  Gen Hosp Psychiatry       Date:  2008 Jul-Aug       Impact factor: 3.238

8.  Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.

Authors:  Joo-Cheol Shim; Jae-Goo K Shin; Deanna L Kelly; Do-Un Jung; Young-Soo Seo; Kwang-Hyeon Liu; Ji-Hong Shon; Robert R Conley
Journal:  Am J Psychiatry       Date:  2007-09       Impact factor: 18.112

9.  Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.

Authors:  F Bogazzi; S Buralli; L Manetti; V Raffaelli; T Cigni; M Lombardi; F Boresi; S Taddei; A Salvetti; E Martino
Journal:  Int J Clin Pract       Date:  2008-05-06       Impact factor: 2.503

10.  The effect of neuroleptics on prolactinoma growth in a Jordanian schizophrenic girl.

Authors:  T K Daradkeh; K M Ajlouni
Journal:  Acta Psychiatr Scand       Date:  1988-02       Impact factor: 6.392

View more
  7 in total

1.  Regarding "A Risperidone-induced Prolactinoma Resolved When A Woman with Schizoaffective Disorder Switched to Ziprasidone: A Case Report".

Authors:  Danielle Coppola; Shanker Thiagarajah; Hong Qiu; David Hough
Journal:  Innov Clin Neurosci       Date:  2013-02

Review 2.  Dopaminergic Pathways in Obesity-Associated Inflammation.

Authors:  Fernanda Leite; Laura Ribeiro
Journal:  J Neuroimmune Pharmacol       Date:  2019-07-17       Impact factor: 4.147

3.  Cabergoline associated with first episode mania.

Authors:  Yael T Harris; Alexander Z Harris; Jose M Deasis; Stephen J Ferrando; Nirmala Reddy; Robert C Young
Journal:  Psychosomatics       Date:  2012-05-31       Impact factor: 2.386

Review 4.  The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.

Authors:  J Peuskens; L Pani; J Detraux; M De Hert
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

5.  Management of a microprolactinoma with aripiprazole in a woman with cabergoline-induced mania.

Authors:  Lisa Burback
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2015-10-06

Review 6.  Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist.

Authors:  Anastasia P Athanasoulia-Kaspar; Kathrin H Popp; Gunter Karl Stalla
Journal:  Endocr Connect       Date:  2018-01-29       Impact factor: 3.335

7.  Hashimoto's Encephalopathy Revealed by Hypochondriacal Delusion: A Case Report Involving a Male Patient.

Authors:  Badii Amamou; Imen Ben Saida; Amjed Ben Haouala; Ahmed Mhalla; Ferid Zaafrane; Lotfi Gaha
Journal:  Am J Mens Health       Date:  2020 Sep-Oct
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.